LLY Trade Ideas
CommonQuant has published 13 trade ideas mentioning LLY.
Recent trade ideas mentioning LLY
Defensive growth shines as rate fears ease — ride Eli Lilly's GLP-1 dominance
LONG · 2026-07-04The broader stock market is breathing a sigh of relief as cooling job numbers ease fears of aggressive rate hikes. This favorable environment for stocks is the perfect backdrop for high-flying growth stories like Eli Lilly, which just secured massive Medicare coverage for its weight-loss drugs.
Healthcare stocks are breaking out on fundamental wins — accumulate Eli Lilly
LONG · 2026-07-04Healthcare and biotech stocks are surging on massive fundamental wins, from Eli Lilly's Medicare expansion to Moderna's FDA approval. With Goldman Sachs noting that broad capital spending is powering the bull market, defensive sectors with strong catalysts are attracting heavy institutional investment.
Dow hits record highs as Tesla and Lilly crush it — rotate into old-economy winners
LONG · 2026-07-03Tesla just crushed its delivery numbers, joining other non-tech companies like Eli Lilly in pushing the Dow to record highs. Meanwhile, AI-related tech stocks like Micron are getting crushed by supply fears—this is a clear signal that old-economy stocks are taking the market's spotlight.
Defensive rotation: Dow hits record highs while tech bleeds — accumulate Eli Lilly
LONG · 2026-07-03The old-school Dow Jones hit a record high thanks to defensive stocks like Eli Lilly, while tech stocks took a hit. With the economy slowing down and unemployment ticking up, investors are moving their money into healthcare companies whose sales are protected by government Medicare coverage.
Eli Lilly's obesity drug data impresses analysts — jump back into the weight-loss leader
LONG · 2026-06-09Eli Lilly's stock is climbing after presenting highly anticipated new data on its obesity and diabetes drugs at a major medical conference. Analysts confirm the company's lineup remains incredibly strong.
Eli Lilly's next-gen weight-loss drug crushes it — ride the momentum in pharma stocks
LONG · 2026-06-09Eli Lilly just released highly encouraging results for its newest weight-loss drug, sending the stock sharply higher in early trading.
Eli Lilly's new weight-loss drug wows Wall Street — ride the breakout higher
LONG · 2026-06-09Eli Lilly just released highly anticipated results for its next-generation weight-loss drug, and the data impressed experts enough to send the stock jumping before the market even opened.
Eli Lilly's new weight-loss drug crushes trials — ride the breakout higher
LONG · 2026-06-09Eli Lilly's stock is surging after the company announced highly successful late-stage trial results for its next-generation weight-loss drug, exciting analysts and reinforcing confidence in its portfolio.
Weight-loss drugs are crushing it and big pharma is on a buying spree — jump on Eli Lilly and biotech
LONG · 2026-06-09Eli Lilly just reported stellar results for its next weight-loss drug, and massive buyouts are sweeping the pharmaceutical industry as companies race to snap up the next big medical breakthrough.
Eli Lilly's new weight-loss drug crushes expectations — accumulate pharma suppliers
LONG · 2026-06-09Eli Lilly just released highly positive results for its new next-generation weight-loss drug. Analysts are impressed, and the stock is jumping as the company proves its entire portfolio of drugs is incredibly strong.
Eli Lilly's next-gen weight-loss drug crushes it in trials — load up on obesity drug stocks
LONG · 2026-06-09Eli Lilly just released highly anticipated results for its next-gen weight-loss drug, and the data looks incredibly promising. Analysts are cheering, saying the company's lineup is strong enough to dominate the multi-billion dollar obesity market for years.
Eli Lilly's new weight-loss drug crushes trials — ride the obesity drug wave
LONG · 2026-06-09Eli Lilly just released highly anticipated results for its next-generation weight-loss drug, and the data is incredibly strong. Analysts are raving about the drug, saying the company's portfolio is built for long-term dominance, sending the stock sharply higher.